“We’re seeing increased demand for Parse’s Evercode single cell sequencing solutions across Asia, and we believe our products are poised for widespread adoption in India, as well,” noted Parse Biosciences CEO and co-founder Alex Rosenberg, Ph.D. “By partnering with Spinco, we are enabling their research community a way to easily adopt the leading single cell sequencing technology.”

The company’s agreement with Spinco Biotech will give researchers in India full access to its single cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, CRISPR Detect, and the Parse Biosciences data analysis solution. The agreement is a continuation of Parse’s ongoing introduction of its products in key international markets, which are also currently available in North America, Europe, Australia, South Korea, Singapore, Israel, and New Zealand.

Noted Spinco Biotech founder and chairman Thyagarajan Srinivasan, “Parse is an important pioneer in single cell sequencing, and researchers here will greatly benefit from its Evercode technology. We're thrilled to partner with Parse to introduce this state of the art technology to India’s biotech community.”